Vaishali Pharma Ltd.

Certification Partner Global
ISO 9001 : 2015 Certified

GOVT. RECOGNIZED
STAR EXPORT HOUSE

CORPORATE & REGISTERED OFFICE :
706-709, 7th Floor, Aravali Business Centre,
R. C. Patel Road, Off. Sodawala Lane,
Borivali (West), Mumbai-400 092.
Tel.: +91-22-4217 1819
E-mail : sales@vaishalipharma.com
CIN - L52310MH2008PLC181632

31st December, 2020

To,
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor, Plot No. C/1,
G Block, Bandra-Kurla Complex,
Bandra (East), Mumbai – 400 051

Stock Code: VAISHALI

Dear Sir/Madam,

SUB: RECEIVED THE APPROVAL & REGISTRATION FOR FIVE NEW PRODUCTS IN THE DEVELOPING MARKET OF TURKMENISTAN.

We are very pleased to inform our shareholders that after the implementation of very hard work and planned marketing strategies, the Company has **received Approval and Registration for Five new products in the Developing Market of Turkmenistan.**

Please find enclosed herewith a copy of Press Release giving information about the same and many more.

We request you to kindly take the same on record.

Thanking you.

Yours faithfully,
For Vaishali Pharma Limited

Akshay Jharkhandi

Akshay Jharkhandi
Company Secretary

VAISHALI PHARMA LTD. * MUMBAI *

PRESS RELEASE

RECEIVED THE APPROVAL & REGISTRATION FOR FIVE NEW PRODUCTS IN THE DEVELOPING MARKET OF TURKMENISTAN.

Mumbai, December 31, 2020: Vaishali Pharma Limited (NSE:- VAISHALI), a Mumbai based Company, engaged in supply of pharmaceutical products to corporates, hospitals and retails stores in all SKUs required. Our products have made its grasp on the overseas market and getting an excellent feedback worldwide. The Company is showing consistent agility and innovation by meeting the needs of its customers in both Domestic and International markets.

We are pleased to inform our shareholders that with the hard work of our Team, and continuous survey and research along with the supports of our partners the Company received the **Approval and Registration for Five new products from the Ministry of Health and Medicine of Turkmenistan**. These products have a good demand in the local markets of Turkmenistan. This remarkable achievement in the symbolizes a landmark and enables the Company to strengthen its presence in the high growth market of Turkmenistan and enables the Company to reach out to more and more territories. The Company also plans to register the similar range of products in the neighboring Countries.

Turkmenistan Health care industry has shown one of the strongest growth rates in the Central Asia region with annual spending growth rate of around 18% and CAGR for coming five years is expected to be over 12%. Government has developed strong health care modernization plan.

The Following are the products which have received Approval & Registrations:

Sr No.	Product Name	Country	Packing Type	Therapeutic usage
1	**VEGAFLU**	Turkmenistan	Sachets	It helps from Infectious-inflammatory diseases (SARS, influenza) accompanied by a high fever, severe chills, body ache, headache and muscle pain, runny nose, nasal congestion, sneezing
2	**VIPRIN 75**	Turkmenistan	Tablets	An antiplatelet medicine used to treat and prevent heart attacks, strokes and heart-related chest pain (angina). It helps to prevent the formation of blood clots in your blood vessels. It is a very widely used medicine for heart protection.
3	**VIPROAZ - SUSPENSION**	Turkmenistan	Bottle	It is used to treat heartburn, indigestion, acidity, or sour stomach. The Increases the rate of expulsion of gases from the stomach and thus helps in relieving the pain
4	**MALPHAREX**	Turkmenistan	Tablets	It is used to treat common cold symptoms. It thins mucus in the nose, windpipe and lungs making it easier to cough out. It provides relief from seasonal allergic conditions such

				as runny nose, watery eyes, sneezing and congestion or stuffiness
5	**CELLARGY**	Turkmenistan	Tablets	It is used to treat various allergic conditions such as hay fever, conjunctivitis and some skin reactions, and reactions to bites and stings. It relieves watery eyes, runny nose, sneezing, and itching.

Mr. Atul Arvind Vasani, Chairman and Managing Director of the Company says that: "*In this Covid-19 Pandemic, we are very happy to share that our Company has received the* ***approval and registration of five new product in high growth market of Turkmenistan****. These products of* ***Vegaflu, Viprin 75, Viproaz - Suspension, Malpharex and Cellargy*** *have a very good demand in the Turkmenistan market. This remarkable achievement will further strengthen the Company's presence in Turkmenistan market and enhance stronger relations with our clients. Our Company will benefit from the larger sale of products in these markets. This is yet another important step towards laying a strong foundation and meeting our desired targets. Our Company is in a phase of evolution and growth and we will strive hard and deliver on the expected lines.*

I would like to thank the entire team of 'Vaishali Pharma Ltd.' for their untiring efforts, hard work, sincerity and high dedication."

ABOUT VAISHALI PHARMA LIMITED:

Vaishali Pharma Limited (NSE: VAISHALI), abided by the norms of extending uncompromised quality products, has raised the standards of the Pharmaceutical & Healthcare industry time and again. Through unwavering dedication, consistent efforts and endless innovation we enjoy an Export House status. Company's products' quality is certified by ISO 9001:2015 certification for the Quality Management from ISC Global.

In business since 1989, Vaishali Pharma Limited is a globally well trusted brand with high quality products, accepted by companies across the globe. The Company is amongst the leading players in the supply of pharma products – Bulk Drugs / APIs, Formulations, Surgical Products, Veterinary supplements, Herbal & Nutraceutical products, with a well-established brand known for its high-quality products & services amongst various clients globally. The company has over 150+ formulation brands marketed in multiple countries; of which dossier is in CTD format along with its respective bioequivalence. The company has built a robust pipeline of around 250 Dossiers. The Company's synergistic collaboration with WHO-GMP manufacturing facilities is backed by an excellent rapport with clients.

Strong commitment of providing quality products is backed by in-depth industry knowledge, well-qualified team of professionals, as well as hi-tech and advanced infrastructure. Resulting in creating mutually beneficial associations for all the clients.

Adapting quickly to the ever-evolving demands, the Company has emerged as one of the fastest growing organization in the pharmaceutical industry in export of healthcare products from India. With headquarters located in the economic hub of India, Mumbai.

At Vaishali Pharma, we are working tirelessly to make available health improving pharmaceutical products affordable and accessible to all. Looking beyond this immediate term, the upcoming half year shall present more good opportunities for the Company and we shall continue to perform better than the previous half year.

Adhering to high quality standards is not an accident but our habit. Passionate to be the best, we take pride in what we do and strive to deliver products with zero defects. One can count upon us for quality pharmaceutical and healthcare products.

For more details please visit: www.vaishalipharma.com
For any Investor Relations query, please contact:

Mr. Akshay Jharkhandi **Company Secretary** Email: cs@vaishalipharma.com	**Mr. Ratnesh Singh** **Chief Financial Officer** Email: investor@vaishalipharma.com

Note: Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other risk factors, viewers are cautioned not to place undue reliance on these forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.